Day One Biopharmaceuticals (DAWN) News Today → Everybody laughed when he recommended Netflix (From Stansberry Research) (Ad) Free DAWN Stock Alerts $16.01 -0.16 (-0.99%) (As of 02:27 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 20 at 7:12 AM | americanbankingnews.comInsider Selling: Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Insider Sells 2,267 Shares of StockMay 20 at 6:27 AM | americanbankingnews.comDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN) General Counsel Sells $52,308.24 in StockMay 20 at 6:27 AM | americanbankingnews.comDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN) CFO Charles N. York II Sells 2,675 SharesMay 19 at 7:00 AM | americanbankingnews.comJeremy Bender Sells 7,873 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) StockMay 18 at 10:41 AM | insidertrades.comSamuel C. Blackman Sells 2,267 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) StockMay 17 at 7:57 PM | marketbeat.comDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Insider Sells $36,453.36 in StockDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Get Free Report) insider Samuel C. Blackman sold 2,267 shares of the business's stock in a transaction dated Thursday, May 16th. The shares were sold at an average price of $16.08, for a total value of $36,453.36. Following the completion of the sale, the insider now directly owns 1,171,081 shares of the company's stock, valued at approximately $18,830,982.48. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.May 15, 2024 | marketbeat.comNicholas Investment Partners LP Sells 1,885,336 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)Nicholas Investment Partners LP lessened its stake in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) by 86.1% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 303,318 shares of the company's stock after selling 1,May 15, 2024 | insidertrades.comInsider Selling: Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Insider Sells 10,000 Shares of StockMay 12, 2024 | americanbankingnews.comDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Given Consensus Rating of "Moderate Buy" by AnalystsMay 11, 2024 | americanbankingnews.comQ2 2024 Earnings Estimate for Day One Biopharmaceuticals, Inc. Issued By Wedbush (NASDAQ:DAWN)May 10, 2024 | marketbeat.comDay One Biopharmaceuticals, Inc. Forecasted to Post Q2 2024 Earnings of ($0.75) Per Share (NASDAQ:DAWN)Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) - Stock analysts at Wedbush dropped their Q2 2024 earnings per share estimates for Day One Biopharmaceuticals in a research note issued on Tuesday, May 7th. Wedbush analyst R. Driscoll now anticipates that the company will post earningsMay 10, 2024 | americanbankingnews.comFY2027 EPS Estimates for Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Decreased by AnalystMay 10, 2024 | americanbankingnews.comDay One Biopharmaceuticals, Inc. to Post Q3 2024 Earnings of ($0.69) Per Share, HC Wainwright Forecasts (NASDAQ:DAWN)May 10, 2024 | americanbankingnews.comCapital One Financial Comments on Day One Biopharmaceuticals, Inc.'s Q2 2024 Earnings (NASDAQ:DAWN)May 9, 2024 | marketbeat.comFY2027 EPS Estimates for Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Lowered by AnalystDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) - Analysts at Wedbush reduced their FY2027 earnings per share estimates for shares of Day One Biopharmaceuticals in a research report issued to clients and investors on Tuesday, May 7th. Wedbush analyst R. Driscoll now expects that theMay 9, 2024 | marketbeat.comTimesSquare Capital Management LLC Has $24.33 Million Holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)TimesSquare Capital Management LLC raised its position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) by 45.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,666,065 shares of the company's stock afterMay 8, 2024 | markets.businessinsider.comBuy Rating for Day One Biopharmaceuticals Amidst DAY101 Approval and Strong Market EntryMay 8, 2024 | markets.businessinsider.comBuy Rating on Day One Biopharmaceuticals: Ojemda’s Market Potential and Strategic CommercializationMay 7, 2024 | marketbeat.comDay One Biopharmaceuticals (NASDAQ:DAWN) Given Outperform Rating at WedbushWedbush reaffirmed an "outperform" rating and set a $33.00 price target on shares of Day One Biopharmaceuticals in a research report on Tuesday.May 7, 2024 | finanznachrichten.deDay One Biopharmaceuticals, Inc.: Day One Reports First Quarter 2024 Financial Results and Corporate ProgressMay 7, 2024 | msn.comIndegene IPO subscribed 7.34 times on Day 2May 7, 2024 | marketbeat.comHC Wainwright Lowers Day One Biopharmaceuticals (NASDAQ:DAWN) Price Target to $40.00HC Wainwright decreased their target price on Day One Biopharmaceuticals from $50.00 to $40.00 and set a "buy" rating for the company in a research report on Tuesday.May 6, 2024 | globenewswire.comDay One Reports First Quarter 2024 Financial Results and Corporate ProgressMay 6, 2024 | marketbeat.comDay One Biopharmaceuticals (NASDAQ:DAWN) Shares Gap Down on Insider SellingDay One Biopharmaceuticals (NASDAQ:DAWN) Shares Gap Down After Insider SellingMay 4, 2024 | insidertrades.comDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN) CFO Charles N. York II Sells 8,078 SharesMay 4, 2024 | finance.yahoo.comInsider Sale at Day One Biopharmaceuticals Inc (DAWN)May 3, 2024 | marketbeat.comDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN) CFO Sells $144,192.30 in StockDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Get Free Report) CFO Charles N. York II sold 8,078 shares of Day One Biopharmaceuticals stock in a transaction on Friday, May 3rd. The shares were sold at an average price of $17.85, for a total value of $144,192.30. Following the completion of the transaction, the chief financial officer now owns 217,293 shares of the company's stock, valued at $3,878,680.05. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.May 1, 2024 | marketbeat.comDay One Biopharmaceuticals (NASDAQ:DAWN) Reaches New 52-Week High at $17.87Day One Biopharmaceuticals (NASDAQ:DAWN) Sets New 1-Year High at $17.87April 29, 2024 | marketbeat.comDay One Biopharmaceuticals (NASDAQ:DAWN) Trading 5.2% Higher Day One Biopharmaceuticals (NASDAQ:DAWN) Stock Price Up 5.2%April 25, 2024 | marketbeat.comDay One Biopharmaceuticals (NASDAQ:DAWN) Stock Price Down 10.9%Day One Biopharmaceuticals (NASDAQ:DAWN) Shares Down 10.9%April 24, 2024 | msn.comDay One slips despite Ojemda approval as BofA says label “not a home run”April 24, 2024 | seekingalpha.comDay One Pharmaceuticals: Ojemda Approval A Big Win, Current Valuation FairApril 24, 2024 | marketbeat.comDay One Biopharmaceuticals' (DAWN) "Outperform" Rating Reiterated at WedbushWedbush reissued an "outperform" rating and set a $33.00 price objective on shares of Day One Biopharmaceuticals in a report on Wednesday.April 24, 2024 | marketbeat.comDay One Biopharmaceuticals (NASDAQ:DAWN) Sees Large Volume Increase Following Analyst UpgradeDay One Biopharmaceuticals (NASDAQ:DAWN) Sees Large Volume Increase on Analyst UpgradeApril 24, 2024 | marketbeat.comDay One Biopharmaceuticals (NASDAQ:DAWN) Price Target Raised to $33.00 at Needham & Company LLCNeedham & Company LLC upped their target price on Day One Biopharmaceuticals from $30.00 to $33.00 and gave the stock a "buy" rating in a report on Wednesday.April 23, 2024 | markets.businessinsider.comBuy Rating on Day One Biopharmaceuticals Amid FDA Approval and Strong Market ProspectsApril 23, 2024 | markets.businessinsider.comBuy Rating Affirmed for Day One Biopharmaceuticals Following FDA Approval of OjemdaApril 23, 2024 | finance.yahoo.comDay One’s OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain TumorApril 23, 2024 | globenewswire.comDay One's OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain TumorApril 23, 2024 | marketbeat.comDay One Biopharmaceuticals (NASDAQ:DAWN) Trading Up 12.2% on Analyst UpgradeDay One Biopharmaceuticals (NASDAQ:DAWN) Trading Up 12.2% After Analyst UpgradeApril 23, 2024 | insidertrades.comDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Insider Samuel C. Blackman Sells 10,000 SharesApril 22, 2024 | markets.businessinsider.comBuy Rating Affirmed for Day One Biopharmaceuticals on Strong Tovorafenib Prospects and Market ImpactApril 22, 2024 | marketbeat.comDay One Biopharmaceuticals (NASDAQ:DAWN) Shares Gap Up Following Analyst UpgradeDay One Biopharmaceuticals (NASDAQ:DAWN) Shares Gap Up on Analyst UpgradeApril 22, 2024 | marketbeat.comDay One Biopharmaceuticals (NASDAQ:DAWN) PT Raised to $36.00 at JPMorgan Chase & Co.JPMorgan Chase & Co. lifted their price objective on shares of Day One Biopharmaceuticals from $32.00 to $36.00 and gave the stock an "overweight" rating in a research note on Monday.April 19, 2024 | marketbeat.comDay One Biopharmaceuticals (NASDAQ:DAWN) Shares Down 4.7% Day One Biopharmaceuticals (NASDAQ:DAWN) Trading Down 4.7%April 18, 2024 | marketbeat.comDay One Biopharmaceuticals (NASDAQ:DAWN) Sees Strong Trading VolumeDay One Biopharmaceuticals (NASDAQ:DAWN) Sees Unusually-High Trading VolumeApril 16, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: OptimizeRx (OPRX), Day One Biopharmaceuticals (DAWN)April 16, 2024 | marketbeat.comDay One Biopharmaceuticals (NASDAQ:DAWN) Trading 3.8% Higher Day One Biopharmaceuticals (NASDAQ:DAWN) Trading 3.8% HigherApril 16, 2024 | marketbeat.comDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Short Interest Down 6.6% in MarchDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Get Free Report) was the target of a large drop in short interest during the month of March. As of March 31st, there was short interest totalling 8,980,000 shares, a drop of 6.6% from the March 15th total of 9,610,000 shares. Currently, 15.2% of the company's stock are short sold. Based on an average daily trading volume, of 619,200 shares, the days-to-cover ratio is presently 14.5 days.April 10, 2024 | markets.businessinsider.comBuy Rating on Day One Biopharmaceuticals Ahead of Tovorafenib PDUFA Date and Potential for Market Disruption Get Day One Biopharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for DAWN and its competitors with MarketBeat's FREE daily newsletter. Email Address A once-in-a-century investment opportunity (Ad)It's an under-the-radar stock reshaping a projected $109 billion industry - And, I believe, has far more potential than the AI stocks most investors are focused on in the days ahead. To get its name and ticker symbol for free - just click here. DAWN Media Mentions By Week DAWN Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. DAWN News Sentiment▼-0.010.42▲Average Medical News Sentiment DAWN News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. DAWN Articles This Week▼132▲DAWN Articles Average Week Get Day One Biopharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for DAWN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Avadel Pharmaceuticals News Today Dynavax Technologies News Today Pacira BioSciences News Today Morphic News Today Akero Therapeutics News Today ANI Pharmaceuticals News Today Kiniksa Pharmaceuticals News Today Gemini Therapeutics News Today Ligand Pharmaceuticals News Today Gyre Therapeutics News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:DAWN) was last updated on 5/20/2024 by MarketBeat.com Staff From Our PartnersDems have chosen Biden replacement?Paradigm PressDoes this make you sick?Allegiance GoldThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldProtect Your Bank Account Before It’s Too LateWeiss RatingsThis Apple-like Innovator is Revolutionizing HealthcareWall Street Star**Breaking News** LIttle Known Biotech Company Does $41 Million In Q1! Huge AlertsThis Could be Your “Big Money” AI MomentInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Day One Biopharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
